SCHEMBL5098035

SCHEMBL5098035

Cc1ccc(-c2nnc(C34CC5CC(CC(C5)C3)C4)n2Cc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.57
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
OPRK1 P41145 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5092071 0.92 HSD11B1 (0.63) HSD11B1ALDH1A1HPGDGAAKDM4E
SCHEMBL5105050 0.90 HSD11B1 (0.54) HSD11B1ALDH1A1HPGDTSHRTP53
SCHEMBL5098753 0.81 HSD11B1 (0.68) HSD11B1ALDH1A1HPGDGAAMEN1
SCHEMBL5104754 0.79 HSD11B1 (0.67) HSD11B1MEN1KMT2ATP53NPSR1
SCHEMBL5095890 0.79 HSD11B1 (0.69) HSD11B1ALDH1A1TSHRSMN1; SMN2ADORA3
SCHEMBL3012641 0.78 ALDH1A1 (0.60) ALDH1A1HPGDGAAMEN1KMT2A
SCHEMBL5104580 0.78 HSD11B1 (0.47) HSD11B1ALDH1A1MEN1KMT2ATSHR
SCHEMBL5098106 0.77 HSD11B1 (0.66) HSD11B1ALDH1A1HPGDKDM4ETSHR
SCHEMBL5092195 0.76 HSD11B1 (0.78) HSD11B1ALDH1A1HPGDGAAMEN1
SCHEMBL5098790 0.76 HSD17B10 (0.46) HSD11B1ALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-20050070720-A1 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070720-A1 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885ALDH1A1 688/4885HPGD 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.